Cryoport Inc

Cryoport Inc(CYRX)股票分析

$17.980

+0.151 (+0.84%)收盤時

Loading chart…
最高
18.000
開盤
17.740
成交量加權均價
17.75
成交量
529.51K
市值
337.41M
最低
17.276
成交金額
9.40M
企業價值/稅息折舊攤銷前利潤(TTM)
-47.44

Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others.

AI 分析 of Cryoport Inc (CYRX)

買進

Cryoport Inc (CYRX) appears to be a good buy right now due to its current price of $17.98, which is below the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +88.08% and a recent 5-day change of +6.77%, indicating positive momentum. However, the main risk is its forward P/E ratio of 79.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the near future.

分析師評級(4)

-38.82% 下跌空間
買進
4 買進
0 持有
0 賣出
目前: 17.98
最低
11.00
平均
11.00
最高
11.00

Guggenheim

2026-10-01

目標價

$19

買進

Needham

2026-08-07

目標價

$19

買進

Guggenheim

2026-08-07

目標價

$16

買進

Roth Capital

2026-08-07

目標價

$21

買進

BTIG

2026-07-24

目標價

$25

買進

估值指標

Cryoport Inc(CYRX)目前預期本益比為 79.37,5 年平均預期本益比為 -15.39。

預期本益比

高估
5 年均值 P/E
-15.39
目前P/E
79.37
高估
46.70
低估
-77.49

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-16.30
目前EV/EBITDA
-47.44
高估
97.99
低估
-130.59

預期股價營收比

合理
5 年均值 P/S
3.69
目前P/S
4.20
高估
6.17
低估
1.22

Alphio AI 對 CYRX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%CYRX

$5.71

情境價格

基

基準

基準 · 50%CYRX

$5.71

情境價格

悲

悲觀

悲觀 · 25%CYRX

$5.70

情境價格

持有 CYRX 的大戶

B

Brown Capital Management, LLC

+ 持有CYRX

-2.85%

3個月報酬率

CYRX 常見問題 —— 由 Alphio AI 解答

Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others. It operates in the Industrials sector (PHARMACEUTICAL PREPARATIONS industry).

Cryoport Inc (CYRX) appears to be a good buy right now due to its current price of $17.98, which is below the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +88.08% and a recent 5-day change of +6.77%, indicating positive momentum. However, the main risk is its forward P/E ratio of 79.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the near future.

4 analysts cover CYRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易